Spitzbart H, et al. - Researchers reported the outcome of women following systemic treatment of cervical human papilloma virus (HPV) with a leukocyte ultrafiltrate in this preliminary work. For HPV infection, evaluation of cervical brush specimens of 819 women with low-grade CIN-1 was done. Treatment in HPV-positive patients involved either cone biopsy because of suspicious colposcopy or antibiotics for symptoms of bacterial cervicitis. The remaining women were viewed as asymptomatic carriers of HPV and were provided systemic therapy with a human leukocyte ultrafiltrate in a dosage of 5 IE, 6 times in the first 2 weeks, and additionally as a single dose at weeks 4, 6, 8 and 10. Ninety-seven HPV-positive women received the leukocyte ultrafiltrate. During follow-up, HPV negativity was reported in 88.7% at week 6; the remaining 11 women were tested negative after completion of a second course of therapy. These preliminary data support the efficacy of a leukocyte ultrafiltrate for successfully treating HPV infection and hence are very promising.